PARP1 and astrocytoma (excluding glioblastoma): To the best of our knowledge, we hereby present the first comprehensive study that evaluate I) PARP1 CNAs and mRNA expressions, II) its usefulness in GBM subtype prognosis, and III) the associations of PARP1 with specific astrocytoma molecular markers.